Daniel Patrick O’day Sells 10,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $124.83, for a total transaction of $1,248,300.00. Following the sale, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $70,740,911.34. The trade was a 1.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Daniel Patrick O’day also recently made the following trade(s):

• On Friday, November 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $126.54, for a total transaction of $1,265,400.00.
• On Tuesday, October 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00.

Gilead Sciences Stock Down 1.4%

NASDAQ:GILD traded down $1.73 during midday trading on Tuesday, reaching $123.18. The company had a trading volume of 3,245,585 shares, compared to its average volume of 7,846,793. Gilead Sciences, Inc. has a 12-month low of $88.57 and a 12-month high of $128.70. The firm has a market capitalization of $152.83 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 0.69 and a beta of 0.32. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The stock’s fifty day simple moving average is $122.99 and its 200-day simple moving average is $116.80.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.Gilead Sciences’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s payout ratio is 48.99%.

Analysts Set New Price Targets

Several research firms have recently issued reports on GILD. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Sanford C. Bernstein set a $135.00 price target on Gilead Sciences and gave the company an “outperform” rating in a research note on Monday. UBS Group raised Gilead Sciences to a “hold” rating in a research report on Thursday, December 4th. Needham & Company LLC increased their price objective on Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Finally, Truist Financial began coverage on Gilead Sciences in a research report on Monday, November 24th. They set a “buy” rating and a $140.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $131.68.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in GILD. Vanguard Group Inc. increased its stake in shares of Gilead Sciences by 1.6% during the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after acquiring an additional 1,893,401 shares during the period. Geode Capital Management LLC boosted its holdings in Gilead Sciences by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after purchasing an additional 727,515 shares in the last quarter. Norges Bank acquired a new position in Gilead Sciences during the 2nd quarter worth approximately $2,150,268,000. Invesco Ltd. raised its stake in shares of Gilead Sciences by 12.0% during the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after buying an additional 1,618,453 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Gilead Sciences by 12.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after buying an additional 1,520,809 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.